Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

IMPORTANCE: Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an understanding of this combination’s tolerability and impact on minimal residual disease (MRD) negativity because this end point has be...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:JAMA Oncol
المؤلفون الرئيسيون: Korde, Neha, Roschewski, Mark, Zingone, Adriana, Kwok, Mary, Manasanch, Elisabet E., Bhutani, Manisha, Tageja, Nishant, Kazandjian, Dickran, Mailankody, Sham, Wu, Peter, Morrison, Candis, Costello, Rene, Zhang, Yong, Burton, Debra, Mulquin, Marcia, Zuchlinski, Diamond, Lamping, Liz, Carpenter, Ashley, Wall, Yvonne, Carter, George, Cunningham, Schuyler C., Gounden, Verena, Sissung, Tristan M., Peer, Cody, Maric, Irina, Calvo, Katherine R., Braylan, Raul, Yuan, Constance, Stetler-Stevenson, Maryalice, Arthur, Diane C., Kong, Katherine A., Weng, Li, Faham, Malek, Lindenberg, Liza, Kurdziel, Karen, Choyke, Peter, Steinberg, Seth M., Figg, William, Landgren, Ola
التنسيق: Artigo
اللغة:Inglês
منشور في: 2015
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6662597/
https://ncbi.nlm.nih.gov/pubmed/26181891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2015.2010
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة